Organisation paid for research Program year 2025 Source: CMS Open Payments

Tucson Orthopaedic Institute

Neither a doctor nor a teaching hospital

Research payments

$1,931,034

186 payments

Through program year 2025, Tucson Orthopaedic Institute is reported as receiving $1,931,034 in research payments, across 186 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $179,606 5
2024 Research $96,707 7
2023 Research $179,576 23
2022 Research $282,763 28
2021 Research $392,080 49
2020 Research $153,373 37
2019 Research $646,929 37

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boston Scientific Corporation $566,803 33 payments
  2. Fidia Pharma USA Inc. $283,245 6 payments
  3. Pfizer Inc. $231,517 7 payments
  4. Endo Pharmaceuticals Inc. $223,309 26 payments
  5. Novartis Pharmaceuticals Corporation $173,100 8 payments
  6. Zimmer Biomet Holdings, Inc. $158,098 15 payments
  7. Eli Lilly and Company $125,881 1 payment
  8. Stryker Corporation $102,958 47 payments
  9. Flexion Therapeutics, Inc. $33,223 1 payment
  10. Anika Therapeutics, Inc. $26,517 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. Rapid $248,900 16 payments
  2. Eqe7-16-01 $248,345 4 payments
  3. A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $231,373 4 payments
  4. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of En3835 for the Treatment of Adhesive Capsulitis of the Shoulder $186,475 16 payments
  5. Boston Scientific Registry of Radiofrequency RF Ablation S $176,375 9 payments
  6. Rapid $141,528 8 payments
  7. nStride Saline Controlled Study $136,940 11 payments
  8. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity Or Overweight and Chronic Low Back Pain (Triumph-7) $125,881 1 payment
  9. A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy $102,981 2 payments
  10. A Two Part, Randomized, Participant and Investigator-Blinded, 2-Arm, Parallel-Design, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Ngi226 Microparticles on Tendon Regeneration in Patients With Achilles Tendinop $45,657 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record